Session Type: ePosters
Session Title: ePosters
Authors(s): R. Soloaga (1), M. Alderete (2), M. Blanco (3), N. Carrion (1), G. D'urso (3), L. Fernandez Canigia (4), B. Fox (4), D. Godoy (3), C. Irrazabal (2), J. Lauro (5), A. Margari (1), B. Medin (2), J. Pidone (1), A. Racioppi (2), A. Sanchez (4), M. Spoleti (5), S. Valle (2)
Authors Affiliations(s): (1) Hospital Naval Pedro Mallo, Argentina, (2) Instituto Alexander Fleming, Argentina, (3) Hospital El Cruce, Argentina, (4) Hospital Aleman, Argentina, (5) Hospital Zona Norte, Argentina
Background:
Bloodstream infections (BSI) remain a leading cause of death and high healthcare-related costs worldwide. The initial appropriate antimicrobial treatment is critical for reducing mortality in patients with sepsis and several studies have demonstrated that the rapid molecular detection of bloodstream pathogens benefits patient care. BioFire® Blood Culture Identification Panel 2 (BCID2) (BioFire, Salt Lake City, UT) uses a high-order multiplex PCR analysis which includes 23 bacteria, 7 yeast, and 10 antibiotic resistance genes; results are obtained in 1 h. This study aimed to determine the performance of the BCID2 from positive blood cultures and to establish the impact of the rapid result obtained by this method in the antimicrobial treatment of patients with sepsis at 5 hospitals in Argentina.
Methods:A total number of 121 patients and 124 BSI episodes were included, 18.5% (23/124) of them were polymicrobial and 191 strains were recovered from blood cultures using BACT-ALERT (2 hospitals) or BACTEC (3 hospitals) systems. The median age of the patients was 61 years (range: 3 month-91 years). The final identification was made by MALDI-TOF (3 hospitals), VITEK 2C (1 hospital), or by PHOENIX (1 hospital) and the antibiotic susceptibility test was performed by VITEK 2C (4 hospitals) or PHOENIX (1 hospital); other additional antibiotic susceptibility tests for carbapenemase detection included Carba Blue and chromatographic methods.
Results:Regarding microbial identification, the positive and negative agreement between BCID2 and Standard of Care (SOC) was 95% and 99.8% respectively. The BCID2 sensitivity to detect CTX-M, KPC, NDM, VIM, IMP, mecA/C, vanA/B was 100% and the specificity was 100%, 100%, 99%, 99%,100%, 100%, 100% respectively. The time to report by BCID2 since blood cultures were positive was 6.3 h in comparison with 42 h (p<0.05) by SOC. After BCID2 results were reported, antimicrobial treatment changes were made in 57/98 episodes (58%).
Conclusions:FilmArray® BCID2 panel is a reliable method for the detection of critical resistance mechanisms and the microorganisms most frequently isolated from patients with sepsis and the rapid result obtained in 1 h from positive blood cultures is an important tool for the early antimicrobial treatment optimization.
Keyword(s): FilmArray, BCID2, BacteremiaCOI Institutional Grants: Yes
Session Type: ePosters
Session Title: ePosters
Authors(s): R. Soloaga (1), M. Alderete (2), M. Blanco (3), N. Carrion (1), G. D'urso (3), L. Fernandez Canigia (4), B. Fox (4), D. Godoy (3), C. Irrazabal (2), J. Lauro (5), A. Margari (1), B. Medin (2), J. Pidone (1), A. Racioppi (2), A. Sanchez (4), M. Spoleti (5), S. Valle (2)
Authors Affiliations(s): (1) Hospital Naval Pedro Mallo, Argentina, (2) Instituto Alexander Fleming, Argentina, (3) Hospital El Cruce, Argentina, (4) Hospital Aleman, Argentina, (5) Hospital Zona Norte, Argentina
Background:
Bloodstream infections (BSI) remain a leading cause of death and high healthcare-related costs worldwide. The initial appropriate antimicrobial treatment is critical for reducing mortality in patients with sepsis and several studies have demonstrated that the rapid molecular detection of bloodstream pathogens benefits patient care. BioFire® Blood Culture Identification Panel 2 (BCID2) (BioFire, Salt Lake City, UT) uses a high-order multiplex PCR analysis which includes 23 bacteria, 7 yeast, and 10 antibiotic resistance genes; results are obtained in 1 h. This study aimed to determine the performance of the BCID2 from positive blood cultures and to establish the impact of the rapid result obtained by this method in the antimicrobial treatment of patients with sepsis at 5 hospitals in Argentina.
Methods:A total number of 121 patients and 124 BSI episodes were included, 18.5% (23/124) of them were polymicrobial and 191 strains were recovered from blood cultures using BACT-ALERT (2 hospitals) or BACTEC (3 hospitals) systems. The median age of the patients was 61 years (range: 3 month-91 years). The final identification was made by MALDI-TOF (3 hospitals), VITEK 2C (1 hospital), or by PHOENIX (1 hospital) and the antibiotic susceptibility test was performed by VITEK 2C (4 hospitals) or PHOENIX (1 hospital); other additional antibiotic susceptibility tests for carbapenemase detection included Carba Blue and chromatographic methods.
Results:Regarding microbial identification, the positive and negative agreement between BCID2 and Standard of Care (SOC) was 95% and 99.8% respectively. The BCID2 sensitivity to detect CTX-M, KPC, NDM, VIM, IMP, mecA/C, vanA/B was 100% and the specificity was 100%, 100%, 99%, 99%,100%, 100%, 100% respectively. The time to report by BCID2 since blood cultures were positive was 6.3 h in comparison with 42 h (p<0.05) by SOC. After BCID2 results were reported, antimicrobial treatment changes were made in 57/98 episodes (58%).
Conclusions:FilmArray® BCID2 panel is a reliable method for the detection of critical resistance mechanisms and the microorganisms most frequently isolated from patients with sepsis and the rapid result obtained in 1 h from positive blood cultures is an important tool for the early antimicrobial treatment optimization.
Keyword(s): FilmArray, BCID2, BacteremiaCOI Institutional Grants: Yes
Session Type: ePosters
Session Title: ePosters
Authors(s): R. Soloaga (1), M. Alderete (2), M. Blanco (3), N. Carrion (1), G. D'urso (3), L. Fernandez Canigia (4), B. Fox (4), D. Godoy (3), C. Irrazabal (2), J. Lauro (5), A. Margari (1), B. Medin (2), J. Pidone (1), A. Racioppi (2), A. Sanchez (4), M. Spoleti (5), S. Valle (2)
Authors Affiliations(s): (1) Hospital Naval Pedro Mallo, Argentina, (2) Instituto Alexander Fleming, Argentina, (3) Hospital El Cruce, Argentina, (4) Hospital Aleman, Argentina, (5) Hospital Zona Norte, Argentina
Background:
Bloodstream infections (BSI) remain a leading cause of death and high healthcare-related costs worldwide. The initial appropriate antimicrobial treatment is critical for reducing mortality in patients with sepsis and several studies have demonstrated that the rapid molecular detection of bloodstream pathogens benefits patient care. BioFire® Blood Culture Identification Panel 2 (BCID2) (BioFire, Salt Lake City, UT) uses a high-order multiplex PCR analysis which includes 23 bacteria, 7 yeast, and 10 antibiotic resistance genes; results are obtained in 1 h. This study aimed to determine the performance of the BCID2 from positive blood cultures and to establish the impact of the rapid result obtained by this method in the antimicrobial treatment of patients with sepsis at 5 hospitals in Argentina.
Methods:A total number of 121 patients and 124 BSI episodes were included, 18.5% (23/124) of them were polymicrobial and 191 strains were recovered from blood cultures using BACT-ALERT (2 hospitals) or BACTEC (3 hospitals) systems. The median age of the patients was 61 years (range: 3 month-91 years). The final identification was made by MALDI-TOF (3 hospitals), VITEK 2C (1 hospital), or by PHOENIX (1 hospital) and the antibiotic susceptibility test was performed by VITEK 2C (4 hospitals) or PHOENIX (1 hospital); other additional antibiotic susceptibility tests for carbapenemase detection included Carba Blue and chromatographic methods.
Results:Regarding microbial identification, the positive and negative agreement between BCID2 and Standard of Care (SOC) was 95% and 99.8% respectively. The BCID2 sensitivity to detect CTX-M, KPC, NDM, VIM, IMP, mecA/C, vanA/B was 100% and the specificity was 100%, 100%, 99%, 99%,100%, 100%, 100% respectively. The time to report by BCID2 since blood cultures were positive was 6.3 h in comparison with 42 h (p<0.05) by SOC. After BCID2 results were reported, antimicrobial treatment changes were made in 57/98 episodes (58%).
Conclusions:FilmArray® BCID2 panel is a reliable method for the detection of critical resistance mechanisms and the microorganisms most frequently isolated from patients with sepsis and the rapid result obtained in 1 h from positive blood cultures is an important tool for the early antimicrobial treatment optimization.
Keyword(s): FilmArray, BCID2, BacteremiaCOI Institutional Grants: Yes
Session Type: ePosters
Session Title: ePosters
Authors(s): R. Soloaga (1), M. Alderete (2), M. Blanco (3), N. Carrion (1), G. D'urso (3), L. Fernandez Canigia (4), B. Fox (4), D. Godoy (3), C. Irrazabal (2), J. Lauro (5), A. Margari (1), B. Medin (2), J. Pidone (1), A. Racioppi (2), A. Sanchez (4), M. Spoleti (5), S. Valle (2)
Authors Affiliations(s): (1) Hospital Naval Pedro Mallo, Argentina, (2) Instituto Alexander Fleming, Argentina, (3) Hospital El Cruce, Argentina, (4) Hospital Aleman, Argentina, (5) Hospital Zona Norte, Argentina
Background:
Bloodstream infections (BSI) remain a leading cause of death and high healthcare-related costs worldwide. The initial appropriate antimicrobial treatment is critical for reducing mortality in patients with sepsis and several studies have demonstrated that the rapid molecular detection of bloodstream pathogens benefits patient care. BioFire® Blood Culture Identification Panel 2 (BCID2) (BioFire, Salt Lake City, UT) uses a high-order multiplex PCR analysis which includes 23 bacteria, 7 yeast, and 10 antibiotic resistance genes; results are obtained in 1 h. This study aimed to determine the performance of the BCID2 from positive blood cultures and to establish the impact of the rapid result obtained by this method in the antimicrobial treatment of patients with sepsis at 5 hospitals in Argentina.
Methods:A total number of 121 patients and 124 BSI episodes were included, 18.5% (23/124) of them were polymicrobial and 191 strains were recovered from blood cultures using BACT-ALERT (2 hospitals) or BACTEC (3 hospitals) systems. The median age of the patients was 61 years (range: 3 month-91 years). The final identification was made by MALDI-TOF (3 hospitals), VITEK 2C (1 hospital), or by PHOENIX (1 hospital) and the antibiotic susceptibility test was performed by VITEK 2C (4 hospitals) or PHOENIX (1 hospital); other additional antibiotic susceptibility tests for carbapenemase detection included Carba Blue and chromatographic methods.
Results:Regarding microbial identification, the positive and negative agreement between BCID2 and Standard of Care (SOC) was 95% and 99.8% respectively. The BCID2 sensitivity to detect CTX-M, KPC, NDM, VIM, IMP, mecA/C, vanA/B was 100% and the specificity was 100%, 100%, 99%, 99%,100%, 100%, 100% respectively. The time to report by BCID2 since blood cultures were positive was 6.3 h in comparison with 42 h (p<0.05) by SOC. After BCID2 results were reported, antimicrobial treatment changes were made in 57/98 episodes (58%).
Conclusions:FilmArray® BCID2 panel is a reliable method for the detection of critical resistance mechanisms and the microorganisms most frequently isolated from patients with sepsis and the rapid result obtained in 1 h from positive blood cultures is an important tool for the early antimicrobial treatment optimization.
Keyword(s): FilmArray, BCID2, BacteremiaCOI Institutional Grants: Yes